Company news
TG Therapeutics, Inc. news in 2025
TG Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
November 27, 2025
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies
November 18, 2025
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
November 9, 2025
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
November 2, 2025
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
October 30, 2025
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
October 27, 2025
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
September 23, 2025
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
September 7, 2025
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program
September 2, 2025
TG Therapeutics to Participate in the Cantor Global Healthcare Conference
August 27, 2025
TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
August 3, 2025
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
July 29, 2025
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
June 5, 2025
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
June 1, 2025
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
May 30, 2025
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
May 26, 2025
TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance
May 4, 2025
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
April 29, 2025
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
April 7, 2025
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals
April 6, 2025
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
March 6, 2025
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
March 2, 2025
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 26, 2025
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update
February 25, 2025
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
January 13, 2025
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
January 8, 2025
Calls in 2025
Decks in 2025
- J.P. Morgan Healthcare Conference 2025
Conference · 21 slides · January 2025